Davy James, Managing Editor

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the relationship between specialty pharmacies and accountable care organizations.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Most read articles of the week on Specialty Pharmacy Times.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses how expensive hepatitis C drugs have impacted the specialty landscape.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, discusses how specialty pharmacies can enhance their operations with data analytics.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences and continuing education activities.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences and continuing education activities.

Catch up with the top news of the week from The American Journal of Pharmacy Benefits.

Zepatier is a once-daily, fixed-dose combination containing with the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir.

Top stories of the week on Specialty Pharmacy Times.

Zepatier is a once-daily, fixed-dose combination containing with the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Top stories of the week on Specialty Pharmacy Times.

Carfilzomib approved in combination with dexamethasone, or with lenalidomide plus dexamethasone, for patients with relapsed/refractory multiple myeloma.

Carfilzomib approved in combination with dexamethasone, or with lenalidomide plus dexamethasone, for patients with relapsed/refractory multiple myeloma.

David Lassen, chief clinical officer at Prime Therapeutics, discusses important developments in specialty pharmacy.

Study finds that Medicare Part D cost saving projections are based on flawed methodology.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses what comprises an effective pharmacy accreditation program.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Top stories of the week on Specialty Pharmacy Times.

Study shows promising results for previously treated or refractory patients with multiple myeloma.

Marc O'Connor, chief operating officer of Curant Health, discusses potential changes patients of specialty pharmacies may experience in the near future.

Cost of some drugs jump by as much as 20%.

Study shows promising results for previously treated or refractory patients with multiple myeloma.

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Out-of-pocket costs to remain a significant hurdle for patients even after closing of coverage gap.